IMSC 2022

Join Bruker's activities at IMSC 2022 on August 27 – September 2, Maastricht, Netherlands

Seminars

Seminar 1, August 29, 13.00 - 14.00 CEST
"From Single Cell to plasma analysis: unleashing the potential of 4D-Proteomics™ to address biological challenges"


Join us at IMSC2022. Meet our users, in-house experts and collaboration partners at our 4D-Proteomics™ seminar.

Abstract:
As they rely on the use of Parallel Accumulation Serial Fragmentation (PASEF) -based methods, 4D-Proteomics approaches are capable of acquiring peptide MS/MS spectra simultaneously with an extremely high acquisition speed, an increased selectivity and a best-in class sensitivity.

Moreover, an accurate Collisional Cross Section (CCS) is measured for each peptide: its use in the bioinformatic processing pipeline allows to further increase identification sensitivity and quantification accuracy. Learn how those approaches can be used to obtain more information from some of the most challenging proteomics task: from single-cell research to plasma-based diagnosis and crosslinked peptides analysis.

Our speakers will be Prof. Nikolai Slavov from the Northeastern University (Boston, MA, USA "Scaling up single-cell proteomics”, Dr. Hans Wessels from the Radboud University Medical Centre (Nijmegen, Netherlands) "PaSER DIA-NN for personalized M-protein diagnostics" and Dr. Richard Scheltema from the Netherland Proteomics Centre (Utrecht, Netherlands) “Crosslinked peptide analysis”.

Seminar 2, August 30, 13.00 - 14.00 CEST
"Multimodal and Multiomics: Rethinking cancer metabolism through MALDI Imaging"

Abstract:
Whether you are probing the cellular proteome, lipidome or metabolome, MALDI Imaging provides a literal map of molecular expression in the specimen that can be compared to reveal regional changes.

Often, knowing where molecular expression changes can be just as important as knowing if expression changes. This can be especially true if certain compounds are highly spatially concentrated or if molecules co-distribute in specific compartments, vital information that is lost when examining only homogenized samples.

Bruker offers solutions for targeted and untargeted discovery with the most complete molecular range and contextualized spatial information, providing important clues into intercellular communications networks that are integral to cancer growth.

 

To target or not to target: translational imaging & “omics” of single cells

Prof. Ron Heeren, Ph.D., Director and Division Head Imaging Mass Spectrometry, Maastricht MultiModal Molecular Imaging Institute, M4i, Maastricht University, Maastricht, Netherlands

Abstract: 
What is more important: the target or the context? Recent developments in the combination of untargeted (unlabelled) and targeted (using labelled antibodies) mass spectrometry based imaging is revolutionizing complementary imaging and “Omics”. New capabilities that improve throughput and content assist in accelerating the pickup of these new approaches in digital pathology. MS image guided tissue selection, with laser capture microdissection, followed by in-depth metabolomics (or proteomics) analysis is added to this workflow to provide detailed insight in local molecular signalling pathways. In this lecture recent advances and applications in the field of translational molecular imaging in a clinical and immunological setting will be discussed.

Lab Innovation Talks

Lab Innovation Talks

August 31, 2.00 - 3.30 CEST: Spatial Metabolite-ID in pharmaceutical applications
Dr. Tiffany Siegel, Scientist - Mass Spectrometry Imaging at Boehringer Ingelheim Pharma GmbH, Biberach an der Riss, Germany

Abstract:
Metabolite identification is an important step within drug discovery and development. Traditionally, LC-MS-based analytics of body fluids (e.g. plasma, bile, urine) are the dominant technology in this field. We show how metabolite detection in tissue can enhance this approach by combining LC-MS-based identification of metabolites from tissue homogenates with metabolite localization by MALDI-MSI on a single platform in a Spatial Omics-like scenario.

 

September 1, 2.00 -3.30 CEST: Applying Immunopeptidomics to predict clinical immunogenicity
Dr. Duong Nguyen, Octapharma Biopharmaceuticals GmbH, Berlin, Germany

Abstract:
Therapeutic proteins have the potential to induce an anti-drug antibody response that can neutralize the therapeutic effects and contribute to hypersensitivity in patients.

To assess the immunogenicity potential of our therapeutic candidates we apply immunopeptidomics for the identification of immunogenic hotspots and for unravelling the mechanisms that cause immunogenicity.

Booth

Booth

Come and visit also one of our booths and talk to our specialists.

 

For Research Use Only. Not for use in clinical diagnostic procedures.